ChristopherTHagenstadMD

PubMed

• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
  Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard ...> ;The New England journal of medicine. 2018-09-25
• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
  Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y,...> ;The Lancet. Oncology. 2018-03-12
• Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
  Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D...> ;The New England journal of medicine. 2017-09-08
• 2 citations
  Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects wi...
  Sara A. Hurvitz, Linda D. Bosserman, David Chan, Christopher T Hagenstad, Frederick C Kass, Frederick P. Smith, Gladys Rodriguez, Barrett H Childs, Dennis J. Slamon> ;Springerplus. 2014 May 12
• 81 citations
  Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
  Johanna C. Bendell, John Nemunaitis, Sasha Vukelja, Christopher Hagenstad, Luis T. Campos, Robert C. Hermann, Peter Sportelli, L. Gardner, Donald A. Richards> ;Journal of Clinical Oncology. 2011 Nov 20
• A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmen...
  Finn RS, Boer K, Lang I, Parikh RJ, Patel R, Schmidt M, Hagenstad CT, Lim HJ, Pinter T, Amadori D, Chan D, Dichmann R, Kim ST, Randolph S, Slamon DJ, Crown JP> ;J. Clin. Oncol.. 2011-05-20
• 8 citations
  A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
  Sara A. Hurvitz, Heather Allen, Rebecca L. Moroose, David Chan, Christopher T Hagenstad, Steven H. Applebaum, Giribala Patel, Eddie H. Hu, Nancy Ryba, Lii-Shin Lin, He...> ;Clinical Breast Cancer. 2010 Aug 1
• Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.
  Vukelja S, Richards D, Campos LT, Bedell C, Hagenstad C, Hyman W, Letzer J, Gardner L, Sportelli P, Nemunaitis J> ;J. Clin. Oncol.. 2009-05-20
• 643 citations
  A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
  J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David R. Spigel, John Marshall, Allen Lee Cohn, David McCollum, Philip J....> ;Journal of Clinical Oncology. 2009 Feb 10
• A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).
  Allerton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF, Katakkar SB, Khan W, Mehta ND, Greco FA> ;J. Clin. Oncol.. 2006-06-20
• 28 citations
  Inflammatory Myofibroblastic Tumor With Bone Marrow Involvement A Case Report and Review of the Literature
  Christopher T. Hagenstad, Scott E. Kilpatrick, Mark J. Pettenati, Paul D. Savage> ;Archives of Pathology & Laboratory Medicine. 2003 Jul 1
• Cryptococcal aortitis presenting as a ruptured mycotic abdominal aortic aneurysm.
  Deitch, J. S., Plonk, G. W., Hagenstad, C., Hansen, K. J., Peacock, J. E., Ligush, J.> ;J Vasc Surg. 1999 Jul
• Join now to see all